Skip to main navigation
Logo

Press Releases

Press Releases

Date Title View
March 29, 2023 Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
March 29, 2023 Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
March 9, 2023 Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 8, 2023 Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
February 1, 2023 Caribou Biosciences to Participate in Upcoming Investor Conferences
January 3, 2023 Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference

 

 


Toolkit

Print Page

Email Alerts

RSS Feeds

Investor Contact

Main Menu

  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
  • More
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Collaborations
      • Licenses
    • Technology
      • chRDNAs
      • Allogeneic T cells
      • Allogeneic NK cells
      • Scientific Publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • AbbVie programs
      • Clinical trials
    • Careers
      • Job Opportunities
      • Values
      • Spotlights
      • Benefits
        • Summary of Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    Main Menu

    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Collaborations
      • Licenses
    • Technology
      • chRDNAs
      • Allogeneic T cells
      • Allogeneic NK cells
      • Scientific Publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • AbbVie programs
      • Clinical trials
    • Careers
      • Job Opportunities
      • Values
      • Spotlights
      • Benefits
        • Summary of Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    logo

    Caribou Biosciences, Inc.
    2929 7th Street, Suite 105
    Berkeley, CA 94710
    Tel: 510-982-6030
    info@cariboubio.com

    ©  Caribou Biosciences, Inc. All rights reserved.

    02. Footer Copyright Links

    • Privacy Policy
    • Terms of Use

    03. Footer Social Links

    • Twitter
    • linkedin